The research article describes a breakthrough in solid tumor immunotherapy using IL-36γ armored CAR T cells. While traditional CAR T therapies often struggle with antigen heterogeneity and the immunosuppressive tumor microenvironment, this study demonstrates that secreting the pro-inflammatory cytokine IL-36γ allows CAR T cells to effectively eradicate tumors. The primary mechanism involves reprogramming neutrophils into a specialized subset that possesses both tumoricidal activity and antigen-presenting capabilities. These "educated" neutrophils activate the host's own immune system, triggering epitope spreading and the expansion of endogenous T cells that target various tumor antigens. Remarkably, this treatment achieves durable results and long-term immunity without the need for traditional lymphodepleting chemotherapy. Consequently, this strategy offers a promising method for overcoming the biological barriers that typically limit adoptive cell therapies in solid malignancies.

References:

• Zuo Y, Vohwinkel D J, Dong B, et al. IL-36γ armored CAR T cells reprogram neutrophils to induce endogenous antitumor immunity[J]. Cancer Cell, 2025.